---
layout: post
title: "Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment; Guidance for Industry; Correction"
date: 2026-02-05 19:08:36 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-05081
original_published: 2024-03-11 00:00:00 +0000
significance: 8.00
---

# Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment; Guidance for Industry; Correction

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 11, 2024 00:00 UTC
**Document Number:** 2024-05081

## Summary

The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on February 22, 2024. The document announced the availability of a final guidance for industry entitled "Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment." The document was published with an incorrect docket number. This document corrects that error.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/03/11/2024-05081/assessing-covid-19-related-symptoms-in-outpatient-adult-and-adolescent-subjects-in-clinical-trials)
- API: https://www.federalregister.gov/api/v1/documents/2024-05081

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
